Loading...
•
Mar 31, 2023
Ultragenyx Q1 2023 Earnings Report
Ultragenyx reported strong revenue growth driven by Crysvita and Dojolvi, and advanced clinical programs.
Key Takeaways
Ultragenyx reported a 26% increase in total revenue for Q1 2023, driven by Crysvita and Dojolvi. The company is progressing with clinical programs, including UX143 and GTX-102, and reaffirms its 2023 revenue guidance.
Total revenue for Q1 2023 was $100.5 million, a 26% increase compared to Q1 2022.
Crysvita revenue reached $76.0 million, demonstrating 28% growth year-over-year.
Dojolvi revenue was $14.3 million for Q1 2023.
The company reaffirmed its 2023 total revenue guidance of $425 million to $450 million.
Ultragenyx
Ultragenyx
Ultragenyx Revenue by Segment
Revenue by Segment
Crysvita Revenue
CapyFin.comDojolvi Revenue
CapyFin.comEvkeeza Revenue
CapyFin.comMepsevii Revenue
CapyFin.com Forward Guidance
Ultragenyx reaffirms its financial guidance for 2023.
Positive Outlook
- Total revenue is expected to be in the range of $425 million to $450 million.
- Crysvita revenue is projected to be between $325 million and $340 million.
- Dojolvi revenue is anticipated to be in the range of $65 million to $75 million.
- Net cash used in operations is expected to be less than $400 million.
- Phase 2 data and Phase 3 initiation of UX143 expected in mid-2023
Revenue & Expenses
Visualization of income flow from segment revenue to net income